

[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
[ Thu, Aug 10th 2017
] - WOPRAI
David Lebovitz Maintained (ALNY) at Hold with Increased Target to $50 on, Aug 10th, 2017
David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Increased Target from $46 to $50 on, Aug 10th, 2017.
David has made no other calls on ALNY in the last 4 months.
There is 1 other peer that has a rating on ALNY. Out of the 1 peers that are also analyzing ALNY, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- Do Kim of "BMO Capital" Initiated at Buy and Held Target at $73 on, Monday, April 17th, 2017
Contributing Sources
Similar Stocks and Investing Articles
[ Thu, Jul 27th 2017
] - WOPRAI
[ Thu, Jul 27th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Mon, Jul 17th 2017
] - WOPRAI
[ Mon, Jul 17th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Thu, May 19th 2016
] - WOPRAI
[ Fri, Aug 24th 2012
] - WOPRAI
[ Mon, Jul 16th 2012
] - WOPRAI